Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

被引：135

作者：

Berger, S. B. ^{[1
]}

Harris, P. ^{[1
]}

Nagilla, R. ^{[1
]}

Kasparcova, V ^{[1
]}

Hoffman, S. ^{[1
]}

Swift, B. ^{[1
]}

Dare, L. ^{[1
]}

Schaeffer, M. ^{[1
]}

Capriotti, C. ^{[1
]}

Ouellette, M. ^{[2
]}

King, B. W. ^{[2
]}

Wisnoski, D. ^{[2
]}

Cox, J. ^{[2
]}

Reilly, M. ^{[1
]}

Marquis, R. W. ^{[1
]}

Bertin, J. ^{[1
]}

Gough, P. J. ^{[1
,3
]}

机构：

[1] GlaxoSmithKline, Immunoinflammat Therapeut Area, Pattern Recognit Receptor Discovery Performance U, Collegeville, PA 19426 USA

[2] GlaxoSmithKline, Platform Technol & Sci, Collegeville, PA USA

[3] GlaxoSmithKline, Host Def Discovery Performance Unit, Infect Dis Therapeut Area, Collegeville, PA 19426 USA

来源：

CELL DEATH DISCOVERY | 2015年 / 1卷

关键词：

D O I：

10.1038/cddiscovery.2015.9

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Necroptosis and signaling regulated by RIP1 kinase activity is emerging as a key driver of inflammation in a variety of disease settings. A significant amount has been learned about how RIP1 regulates necrotic cell death through the use of the RIP1 kinase inhibitor Necrostatin-1 (Nec-1). Nec-1 has been a transformational tool for exploring the function of RIP1 kinase activity; however, its utility is somewhat limited by moderate potency, off-target activity against indoleamine-2,3-dioxygenase (IDO), and poor pharmacokinetic properties. These limitations of Nec-1 have driven an effort to identify next-generation tools to study RIP1 function, and have led to the identification of 7-Cl-O-Nec-1 (Nec-1s), which has improved pharmacokinetic properties and lacks IDO inhibitory activity. Here we describe the characterization of GSK'963, a chiral small-molecule inhibitor of RIP1 kinase that is chemically distinct from both Nec-1 and Nec-1s. GSK'963 is significantly more potent than Nec-1 in both biochemical and cellular assays, inhibiting RIP1-dependent cell death with an IC50 of between 1 and 4 nM in human and murine cells. GSK'963 is >10 000-fold selective for RIP1 over 339 other kinases, lacks measurable activity against IDO and has an inactive enantiomer, GSK'962, which can be used to confirm on-target effects. The increased in vitro potency of GSK'963 also translates in vivo, where GSK'963 provides much greater protection from hypothermia at matched doses to Nec-1, in a model of TNF-induced sterile shock Together, we believe GSK'963 represents a next-generation tool for examining the function of RIP1 in vitro and in vivo, and should help to clarify our current understanding of the role of RIP1 in contributing to disease pathogenesis.

引用

页数：7

共 28 条

[1]

Cutting Edge: RIP1 Kinase Activity Is Dispensable for Normal Development but Is a Key Regulator of Inflammation in SHARPIN-Deficient Mice [J].

Berger, Scott B. ;

Kasparcova, Viera ;

Hoffman, Sandy ;

Swift, Barb ;

Dare, Lauren ;

Schaeffer, Michelle ;

Capriotti, Carol ;

Cook, Michael ;

Finger, Joshua ;

Hughes-Earle, Angela ;

Harris, Philip A. ;

Kaiser, William J. ;

Mocarski, Edward S. ;

Bertin, John ;

Gough, Peter J. .

JOURNAL OF IMMUNOLOGY, 2014, 192 (12) :5476-5480

[2]

The Adaptor Protein FADD Protects Epidermal Keratinocytes from Necroptosis In Vivo and Prevents Skin Inflammation [J].

Bonnet, Marion C. ;

Preukschat, Daniela ;

Welz, Patrick-Simon ;

van Loo, Geert ;

Ermolaeva, Maria A. ;

Bloch, Wilhelm ;

Haase, Ingo ;

Pasparakis, Manolis .

IMMUNITY, 2011, 35 (04) :572-582

[3]

RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation [J].

Cho, YoungSik ;

McQuade, Thomas ;

Zhang, Haibing ;

Zhang, Jianke ;

Chan, Francis Ka-Ming .

PLOS ONE, 2011, 6 (08)

[4]

A novel role for RIP1 kinase in mediating TNFα production [J].

Christofferson, D. E. ;

Li, Y. ;

Hitomi, J. ;

Zhou, W. ;

Upperman, C. ;

Zhu, H. ;

Gerber, S. A. ;

Gygi, S. ;

Yuan, J. .

CELL DEATH & DISEASE, 2012, 3 :e320-e320

[5]

Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation [J].

Cusson-Hermance, N ;

Khurana, S ;

Lee, TH ;

Fitzgerald, KA ;

Kelliher, MA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (44) :36560-36566

[6]

RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis [J].

Dannappel, Marius ;

Vlantis, Katerina ;

Kumari, Snehlata ;

Polykratis, Apostolos ;

Kim, Chun ;

Wachsmuth, Laurens ;

Eftychi, Christina ;

Lin, Juan ;

Corona, Teresa ;

Hermance, Nicole ;

Zelic, Matija ;

Kirsch, Petra ;

Basic, Marijana ;

Bleich, Andre ;

Kelliher, Michelle ;

Pasparakis, Manolis .

NATURE, 2014, 513 (7516) :90-+

[7]

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury [J].

Degterev A. ;

Huang Z. ;

Boyce M. ;

Li Y. ;

Jagtap P. ;

Mizushima N. ;

Cuny G.D. ;

Mitchison T.J. ;

Moskowitz M.A. ;

Yuan J. .

Nature Chemical Biology, 2005, 1 (2) :112-119

[8]

Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase [J].

Degterev, A. ;

Maki, J. L. ;

Yuan, J. .

CELL DEATH AND DIFFERENTIATION, 2013, 20 (02) :366-366

[9]

Identification of RIP1 kinase as a specific cellular target of necrostatins [J].

Degterev, Alexei ;

Hitomi, Junichi ;

Germscheid, Megan ;

Ch'en, Irene L. ;

Korkina, Olga ;

Teng, Xin ;

Abbott, Derek ;

Cuny, Gregory D. ;

Yuan, Chengye ;

Wagner, Gerhard ;

Hedrick, Stephen M. ;

Gerber, Scott A. ;

Lugovskoy, Alexey ;

Yuan, Junying .

NATURE CHEMICAL BIOLOGY, 2008, 4 (05) :313-321

[10]

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis [J].

Fauster, A. ;

Rebsamen, M. ;

Huber, K. V. M. ;

Bigenzahn, J. W. ;

Stukalov, A. ;

Lardeau, C-H ;

Scorzoni, S. ;

Bruckner, M. ;

Gridling, M. ;

Parapatics, K. ;

Colinge, J. ;

Bennett, K. L. ;

Kubicek, S. ;

Krautwald, S. ;

Linkermann, A. ;

Superti-Furga, G. .

CELL DEATH & DISEASE, 2015, 6 :e1767-e1767

← 1 2 3 →